Skip to main content
Top
Published in: Neurotherapeutics 6/2023

28-09-2023 | Fatigue | Commentary

Optimized Nutrition in Mitochondrial Diseases Correlates with Improved Muscle Fatigue, Strength, and Quality of Life: You Are What You Eat, or Are You?

Authors: Russell P. Saneto, Amel Karaa

Published in: Neurotherapeutics | Issue 6/2023

Login to get access

Excerpt

Mitochondrial diseases are a heterogeneous group of genetic and clinical disorders [1, 2]. Complicating the presentation is the wide spectrum of clinical presentations and varying organ involvement. Energy demands often dictate organ involvement, with organs requiring the highest energy needs becoming the most dysfunctional. The variability of genetics, clinical presentation, and prevalence of mitochondrial disorders, coupled with the rarity of individual diseases, make the investigation of directed treatments difficult. In fact, to date, over 50 clinical trials have been undertaken, yet only a single drug, idebenone, has demonstrated scientific evidence for the European Medicines Agency’s approval for one specific mitochondrial disease, Leber Hereditary Optic Neuropathy (LHON) [3, 4]. …
Literature
1.
go back to reference Saneto RP. Mitochondrial diseases: expanding the diagnosis in the era of genetic testing. J Transl Genet Genom. 2020;4:384–428.PubMedPubMedCentral Saneto RP. Mitochondrial diseases: expanding the diagnosis in the era of genetic testing. J Transl Genet Genom. 2020;4:384–428.PubMedPubMedCentral
2.
go back to reference Emmanuele V, Ganesh J, Vladutiu G, Haas R, Kerr D, Saneto RP, et al. Time to harmonize mitochondrial syndrome nomenclature and classification: a consensus from the North American Mitochondrial Disease Consortium, (NAMDC). Mol Genet and Metab. 2022;136:125–31.CrossRef Emmanuele V, Ganesh J, Vladutiu G, Haas R, Kerr D, Saneto RP, et al. Time to harmonize mitochondrial syndrome nomenclature and classification: a consensus from the North American Mitochondrial Disease Consortium, (NAMDC). Mol Genet and Metab. 2022;136:125–31.CrossRef
3.
go back to reference Russell OM, Gorman GS, Lightolers RN, Turnbull DM. Mitochondrial diseases: hope for the future. Cell. 2020;181:168–88.CrossRefPubMed Russell OM, Gorman GS, Lightolers RN, Turnbull DM. Mitochondrial diseases: hope for the future. Cell. 2020;181:168–88.CrossRefPubMed
4.
go back to reference Karaa A, Klopstock T. Clinical trials in mitochondrial diseases. Handb Clin Neurol. 2023;194:229–50.CrossRefPubMed Karaa A, Klopstock T. Clinical trials in mitochondrial diseases. Handb Clin Neurol. 2023;194:229–50.CrossRefPubMed
5.
go back to reference DiVito D, Wellik A, Burfield J, Peterson, J, Flickinger J, Tindall A, et al. Clinical nutrition in mitochondrial disease correlates to improved muscle fatigue, strength, and quality of life. Neurotherapeutics. 2023 (this issue). DiVito D, Wellik A, Burfield J, Peterson, J, Flickinger J, Tindall A, et al. Clinical nutrition in mitochondrial disease correlates to improved muscle fatigue, strength, and quality of life. Neurotherapeutics. 2023 (this issue).
6.
go back to reference Liesa M, Shirihai OS. Mitochondrial dynamics in the regulation of nutrient utilization and energy expenditure. Cell Metab. 2013;2(17):491–506.CrossRef Liesa M, Shirihai OS. Mitochondrial dynamics in the regulation of nutrient utilization and energy expenditure. Cell Metab. 2013;2(17):491–506.CrossRef
7.
go back to reference Sturm G, Karan KR, Monzel AS, Santhanam B, Taivassalo T, Bris C, et al. OxPhos defects cause hypermetabolism and reduce lifespan in cells and in patients with mitochondrial diseases. Commun Biol. 2023;6:22.CrossRefPubMedPubMedCentral Sturm G, Karan KR, Monzel AS, Santhanam B, Taivassalo T, Bris C, et al. OxPhos defects cause hypermetabolism and reduce lifespan in cells and in patients with mitochondrial diseases. Commun Biol. 2023;6:22.CrossRefPubMedPubMedCentral
8.
go back to reference Kyriazis ID, Vassi E, Alvanou M, Angelakis C, Skaperda Z, Tekos F, et al. The impact of diet upon mitochondrial physiology (Review). Int J Mol Med. 2022;50:135.CrossRefPubMedPubMedCentral Kyriazis ID, Vassi E, Alvanou M, Angelakis C, Skaperda Z, Tekos F, et al. The impact of diet upon mitochondrial physiology (Review). Int J Mol Med. 2022;50:135.CrossRefPubMedPubMedCentral
9.
go back to reference Karaa A, Kriger J, Grier J, Holbert A, Thompson JL, Parikh S, et al. Mitochondrial disease patients’ perception of dietary supplements’ use. Mol Genet Metab. 2016;119:100–8.CrossRefPubMedPubMedCentral Karaa A, Kriger J, Grier J, Holbert A, Thompson JL, Parikh S, et al. Mitochondrial disease patients’ perception of dietary supplements’ use. Mol Genet Metab. 2016;119:100–8.CrossRefPubMedPubMedCentral
10.
go back to reference Zolkipli-Cunningham Z, Xiaxo R, Stoddan A, McCormick EM, Holberts A, Burrill N, et al. Mitochondrial disease patient motivations and barriers to participate in clinical trials. PLoS ONE. 2018;13:e0197513.CrossRefPubMedPubMedCentral Zolkipli-Cunningham Z, Xiaxo R, Stoddan A, McCormick EM, Holberts A, Burrill N, et al. Mitochondrial disease patient motivations and barriers to participate in clinical trials. PLoS ONE. 2018;13:e0197513.CrossRefPubMedPubMedCentral
11.
go back to reference Madsen KL, Buch AE, Cohen BH, Falk MJ, Goldsberry A, Goldstein A, et al. Safety and efficacy of omaveloxolone in patients with mitochondrial myopathy: MOTOR trial. Neurology. 2020;18(94):e687–98.CrossRef Madsen KL, Buch AE, Cohen BH, Falk MJ, Goldsberry A, Goldstein A, et al. Safety and efficacy of omaveloxolone in patients with mitochondrial myopathy: MOTOR trial. Neurology. 2020;18(94):e687–98.CrossRef
12.
go back to reference Karaa A, Haas R, Goldstein A, Vockley J, Cohen BH. A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy. J Cachexia Sarcopenia Muscle. 2020;11(4):909–18.CrossRefPubMedPubMedCentral Karaa A, Haas R, Goldstein A, Vockley J, Cohen BH. A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy. J Cachexia Sarcopenia Muscle. 2020;11(4):909–18.CrossRefPubMedPubMedCentral
13.
go back to reference Karaa A, Haas R, Goldstein A, Vockley J, Weaver WD, Cohen BH. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology. 2018;90:e1212–21. Erratum in: Neurology. 2018;90:669. Erratum in: Neurology. 2018 Nov 20; 91:986.CrossRefPubMedPubMedCentral Karaa A, Haas R, Goldstein A, Vockley J, Weaver WD, Cohen BH. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology. 2018;90:e1212–21. Erratum in: Neurology. 2018;90:669. Erratum in: Neurology. 2018 Nov 20; 91:986.CrossRefPubMedPubMedCentral
Metadata
Title
Optimized Nutrition in Mitochondrial Diseases Correlates with Improved Muscle Fatigue, Strength, and Quality of Life: You Are What You Eat, or Are You?
Authors
Russell P. Saneto
Amel Karaa
Publication date
28-09-2023
Publisher
Springer International Publishing
Published in
Neurotherapeutics / Issue 6/2023
Print ISSN: 1933-7213
Electronic ISSN: 1878-7479
DOI
https://doi.org/10.1007/s13311-023-01445-6

Other articles of this Issue 6/2023

Neurotherapeutics 6/2023 Go to the issue